Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis

Trial Profile

Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2018

At a glance

  • Drugs Secukinumab (Primary) ; Adalimumab; Certolizumab pegol; Etanercept; Golimumab; Infliximab
  • Indications Spondylarthritis
  • Focus Therapeutic Use
  • Acronyms ROC-SPA
  • Most Recent Events

    • 26 Jul 2018 Planned initiation date changed from 1 Jun 2018 to 1 Sep 2018.
    • 28 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top